Phoenix Healthcare Group
China Resources Medical runs private hospitals and clinics across China under state backing.
On the record
Checkpoint: H1 2026 interim results, the first full read after the Mentougou contract loss
The call
A licensed hospital operator with real assets but two straight years of shrinking revenue, falling profit, and a government client walking away.
Phoenix Healthcare Group runs hospitals in China and also sells medical technology contracts. It is hard to replace because it owns hospital buildings and has government licenses, but it is easy to lose ground to because public hospitals run by the government attract most patients, and rival private hospital chains like Aier Eye are winning the smaller number of patients willing to pay for private care. The one thing that could change the story is the company's next earnings report in August 2026: if hospital profits stop falling and its technology business starts growing with real numbers, the decline could reverse, but if profits fall further and technology contracts keep getting cancelled, the company becomes a slowly shrinking business with little room to turn around.
Why
01
AI pressure: None apparent. AI shows up as an 'intelligent healthcare' add-on inside its own hospitals, not as an outside force taking patients away. Could AI do the core job? Unlikely.
02
Bigger players: China's public hospital system, plus private rivals Aier Eye, United Family Healthcare, C-MER. Revenue fell two years straight and a district government just pulled its hospital contracts, moving patients back to public and rival care. Could a giant copy it? Probably.
03
What protects it. Grade III hospital licenses, physical hospital assets, and RMB7.04bn in unused bank credit keep it solvent even as volume shrinks.
What would change this call
H1 2026 interim results (due August 2026) show revenue and profit trend. Reveals whether the two-year revenue and profit decline is stabilising or accelerating.
Any new IOT or hospital-management contract terminations after the June 2026 Mentougou case. Shows whether local governments are continuing to unwind Phoenix's legacy hospital contracts.
Disclosure of quantified intelligent-healthcare/AI-services revenue in FY2026 filings. Indicates whether AI initiatives are becoming a material growth offset to the shrinking core.
Any new IOT or hospital-management contract terminations after the June 2026 Mentougou case. Shows whether local governments are continuing to unwind Phoenix's legacy hospital contracts.
Disclosure of quantified intelligent-healthcare/AI-services revenue in FY2026 filings. Indicates whether AI initiatives are becoming a material growth offset to the shrinking core.
Key numbers
- FY2025 revenue RMB9.18bn, down from RMB9.86bn
- FY2025 profit RMB495.9m, down from RMB565.9m
- Mentougou hospital contracts terminated, effective July 2026
Named risks
- Two consecutive years of revenue decline, RMB10.1bn to RMB9.18bn FY2023-FY2025.
- Hospital IOT contract terminations, e.g. Mentougou District effective 2026-07-01, may continue.
- Stock trading near all-time low, down ~85% from peak of HK$17.2.
- Specialist peers like Aier Eye capturing premium private-hospital segment share.
- Recent CEO transition (Nov 2025) adds leadership continuity uncertainty.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Aier Eye Hospital Group | gaining on | 352 hospitals + 229 clinics end-2024, seeking HK listing 2026 while CR Medical revenue falls |
| New Frontier Health / United Family Healthcare | contesting | 10 hospitals, 1 internet hospital, 24 clinics as of 2025-02-11 in premium private segment |
| China's public hospital system | losing to | Dominates patient volume nationally, structurally limiting private operator growth |
| China Resources Pharmaceutical Group (sister company) | gaining on | Market cap HK$30.5bn vs CR Medical HK$3.3bn as of 2026-07-30 under same parent |
Questions people ask
- Is China Resources Medical (formerly Phoenix Healthcare Group) profitable in 2026?
- Yes but shrinking: FY2025 profit attributable to shareholders was RMB495.9 million, down from RMB565.9 million in FY2024, on revenue that fell to RMB9.176 billion from RMB9.855 billion, per results filed 2026-03-24. A February 2026 profit warning also flagged an H1 2025 profit decline of 17.5% to 8.9% year on year.
- Who owns Phoenix Healthcare Group / China Resources Medical?
- It is an indirect subsidiary of China Resources Healthcare Group Limited, part of the state-owned China Resources (Holdings) conglomerate, confirmed in a filing dated 2025-06-19. Chairman Yu Hai concurrently chairs the parent China Resources Healthcare Group, underscoring tight state-linked control.
- Is China Resources Medical stock a safe investment right now?
- The stock traded near its all-time low of HK$2.34 on 2026-06-26, versus an all-time high of HK$17.2, roughly an 85% drop. Market cap was about HK$3.1 to 3.26 billion as of 2026-07-30, down roughly 40.9% year on year.
- Could AI replace China Resources Medical's hospitals?
- No, physical assets are the moat. AI is displacing diagnostic-support tasks nationally, with over 68 million county-level remote imaging cases handled by AI as of May 2025 in China, but Grade III hospital licenses, owned beds and operating theatres cannot be replaced by software. The company describes AI as a growth add-on, not a threat, as of its February 2026 profit warning.
- Who is China Resources Medical's biggest competitor?
- Aier Eye Hospital Group, a specialist ophthalmology chain with 352 hospitals and 229 clinics in China at end-2024 that is seeking a Hong Kong secondary listing in 2026, is outgrowing China Resources Medical's shrinking general hospital network.
- Is China Resources Medical laying off staff?
- Headcount is roughly flat to slightly down, from 19,953 full-time employees at end-2024 to about 19,687 reported as of 2026-07-09, with no major layoff announcement found in filings, though revenue and profit have both declined for two straight years.
Timeline
- 2026-06-26Terminated Hospital IOT agreements with Mentougou District Government, effective 2026-07-01
- 2026-03-24FY2025 results: revenue RMB9.176bn, profit RMB495.9m, both down year on year
- 2026-02-27Profit warning: H1 2025 profit down 17.5% to 8.9% year on year
- 2025-11-07Zhang Chuang appointed CEO, succeeding Yu Hai who stays as Chairman
- 2025-06-19Confirmed as indirect subsidiary of China Resources Healthcare Group
- 2025-03-25FY2024 results: revenue ~RMB9.855bn, down from RMB10.108bn in 2023
- 2018-10Renamed China Resources Medical Holdings Company Limited
- 2013-11-29IPO on HKEX as Phoenix Healthcare Group Co., Ltd.
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Annual Results Announcement FY2025 (2026-03-24)
- Annual Results Announcement FY2024 (2025-03-25)
- China Resources Medical Profit Slips as Revenue Declines but Dividends Edge Higher (2026-03-24)
- Profit Warning (2026-02-27)
- China Resources Medical Holdings Company (HKG:1515) (2026-06-26)
- gurufocus.com company data (2026-07-30)
- E263028A_CR Medical (2026-06-26)
- China Resources Medical Holdings Company (HKG:1515) (2026-07-09)
- Board Committee Announcement (2025-06-19)
- Appointment and CEO Change (2025-11-07)
- Interim Results Announcement H1 2025 (2025-08-26)
- Aier Eye Seeks Hong Kong Listing For International Growth (2026-04-30)